Ashwin N Ananthakrishnan1, Andrew Cagan2, Vivian S Gainer2, Su-Chun Cheng3, Tianxi Cai3, Elizabeth Scoville4, Gauree G Konijeti4, Peter Szolovits5, Stanley Y Shaw6, Susanne Churchill7, Elizabeth W Karlson8, Shawn N Murphy9, Isaac Kohane10, Katherine P Liao8. 1. Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: aananthakrishnan@partners.org. 2. Research IS and Computing, Partners HealthCare, Charlestown, Massachusetts. 3. Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts. 4. Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts. 5. Massachusetts Institute of Technology, Cambridge, Massachusetts. 6. Harvard Medical School, Boston, Massachusetts; Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts. 7. i2b2 National Center for Biomedical Computing, Brigham and Women's Hospital, Boston, Massachusetts. 8. Harvard Medical School, Boston, Massachusetts; Division of Rheumatology, Allergy and Immunology, Brigham and Women's Hospital, Boston, Massachusetts. 9. Harvard Medical School, Boston, Massachusetts; Research IS and Computing, Partners HealthCare, Charlestown, Massachusetts; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts. 10. Harvard Medical School, Boston, Massachusetts; i2b2 National Center for Biomedical Computing, Brigham and Women's Hospital, Boston, Massachusetts; Children's Hospital Boston, Boston, Massachusetts.
Abstract
BACKGROUND & AIMS: Patients with inflammatory bowel diseases (IBDs) have increased risk for venous thromboembolism (VTE); those who require hospitalization have particularly high risk. Few hospitalized patients with IBD receive thromboprophylaxis. We analyzed the frequency of VTE after IBD-related hospitalization, risk factors for post-hospitalization VTE, and the efficacy of prophylaxis in preventing post-hospitalization VTE. METHODS: In a retrospective study, we analyzed data from a multi-institutional cohort of patients with Crohn's disease or ulcerative colitis and at least 1 IBD-related hospitalization. Our primary outcome was a VTE event. All patients contributed person-time from the date of the index hospitalization to development of VTE, subsequent hospitalization, or end of follow-up. Our main predictor variable was pharmacologic thromboprophylaxis. Cox proportional hazard models adjusting for potential confounders were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: From a cohort of 2788 patients with at least 1 IBD-related hospitalization, 62 patients developed VTE after discharge (2%). Incidences of VTE at 30, 60, 90, and 180 days after the index hospitalization were 3.7/1000, 4.1/1000, 5.4/1000, and 9.4/1000 person-days, respectively. Pharmacologic thromboprophylaxis during the index hospital stay was associated with a significantly lower risk of post-hospitalization VTE (HR, 0.46; 95% CI, 0.22-0.97). Increased numbers of comorbidities (HR, 1.30; 95% CI, 1.16-1.47) and need for corticosteroids before hospitalization (HR, 1.71; 95% CI, 1.02-2.87) were also independently associated with risk of VTE. Length of hospitalization or surgery during index hospitalization was not associated with post-hospitalization VTE. CONCLUSIONS: Pharmacologic thromboprophylaxis during IBD-related hospitalization is associated with reduced risk of post-hospitalization VTE.
BACKGROUND & AIMS:Patients with inflammatory bowel diseases (IBDs) have increased risk for venous thromboembolism (VTE); those who require hospitalization have particularly high risk. Few hospitalized patients with IBD receive thromboprophylaxis. We analyzed the frequency of VTE after IBD-related hospitalization, risk factors for post-hospitalization VTE, and the efficacy of prophylaxis in preventing post-hospitalization VTE. METHODS: In a retrospective study, we analyzed data from a multi-institutional cohort of patients with Crohn's disease or ulcerative colitis and at least 1 IBD-related hospitalization. Our primary outcome was a VTE event. All patients contributed person-time from the date of the index hospitalization to development of VTE, subsequent hospitalization, or end of follow-up. Our main predictor variable was pharmacologic thromboprophylaxis. Cox proportional hazard models adjusting for potential confounders were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: From a cohort of 2788 patients with at least 1 IBD-related hospitalization, 62 patients developed VTE after discharge (2%). Incidences of VTE at 30, 60, 90, and 180 days after the index hospitalization were 3.7/1000, 4.1/1000, 5.4/1000, and 9.4/1000 person-days, respectively. Pharmacologic thromboprophylaxis during the index hospital stay was associated with a significantly lower risk of post-hospitalization VTE (HR, 0.46; 95% CI, 0.22-0.97). Increased numbers of comorbidities (HR, 1.30; 95% CI, 1.16-1.47) and need for corticosteroids before hospitalization (HR, 1.71; 95% CI, 1.02-2.87) were also independently associated with risk of VTE. Length of hospitalization or surgery during index hospitalization was not associated with post-hospitalization VTE. CONCLUSIONS: Pharmacologic thromboprophylaxis during IBD-related hospitalization is associated with reduced risk of post-hospitalization VTE.
Authors: Yngve Falck-Ytter; Charles W Francis; Norman A Johanson; Catherine Curley; Ola E Dahl; Sam Schulman; Thomas L Ortel; Stephen G Pauker; Clifford W Colwell Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Guergana K Savova; James J Masanz; Philip V Ogren; Jiaping Zheng; Sunghwan Sohn; Karin C Kipper-Schuler; Christopher G Chute Journal: J Am Med Inform Assoc Date: 2010 Sep-Oct Impact factor: 4.497
Authors: Andrew Tinsley; Steven Naymagon; Arvind J Trindade; David B Sachar; Bruce E Sands; Thomas A Ullman Journal: J Clin Gastroenterol Date: 2013-01 Impact factor: 3.062
Authors: Daniel L Davenport; H David Vargas; Michael W Kasten; Eleftherios S Xenos Journal: Clin Appl Thromb Hemost Date: 2012-02-16 Impact factor: 2.389
Authors: John Fanikos; Amanda Rao; Andrew C Seger; Gregory Piazza; Elaine Catapane; Xiaohua Chen; Samuel Z Goldhaber Journal: Am J Med Date: 2011-12 Impact factor: 4.965
Authors: Katherine P Liao; Dorothée Diogo; Jing Cui; Tianxi Cai; Yukinori Okada; Vivian S Gainer; Shawn N Murphy; Namrata Gupta; Daniel Mirel; Ashwin N Ananthakrishnan; Peter Szolovits; Stanley Y Shaw; Soumya Raychaudhuri; Susanne Churchill; Isaac Kohane; Elizabeth W Karlson; Robert M Plenge Journal: Ann Rheum Dis Date: 2013-05-28 Impact factor: 19.103
Authors: Amanda A VanDlac; Nick G Cowan; Yiyi Chen; Ross E Anderson; Michael J Conlin; Jeffrey C La Rochelle; Christopher L Amling; Theresa M Koppie Journal: J Urol Date: 2013-10-29 Impact factor: 7.450
Authors: Pablo A Olivera; Stephane Zuily; Paulo G Kotze; Veronique Regnault; Sameer Al Awadhi; Peter Bossuyt; Richard B Gearry; Subrata Ghosh; Taku Kobayashi; Patrick Lacolley; Edouard Louis; Fernando Magro; Siew C Ng; Alfredo Papa; Tim Raine; Fabio V Teixeira; David T Rubin; Silvio Danese; Laurent Peyrin-Biroulet Journal: Nat Rev Gastroenterol Hepatol Date: 2021-08-27 Impact factor: 46.802
Authors: Katherine P Liao; Ashwin N Ananthakrishnan; Vishesh Kumar; Zongqi Xia; Andrew Cagan; Vivian S Gainer; Sergey Goryachev; Pei Chen; Guergana K Savova; Denis Agniel; Susanne Churchill; Jaeyoung Lee; Shawn N Murphy; Robert M Plenge; Peter Szolovits; Isaac Kohane; Stanley Y Shaw; Elizabeth W Karlson; Tianxi Cai Journal: PLoS One Date: 2015-08-24 Impact factor: 3.240
Authors: Katherine P Liao; Tianxi Cai; Guergana K Savova; Shawn N Murphy; Elizabeth W Karlson; Ashwin N Ananthakrishnan; Vivian S Gainer; Stanley Y Shaw; Zongqi Xia; Peter Szolovits; Susanne Churchill; Isaac Kohane Journal: BMJ Date: 2015-04-24